N-(benzo[d][1,3]dioxol-5-ylmethyl)-[1,1′-biphenyl]-2-carboxamide | 332129-81-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(benzo[d][1,3]dioxol-5-ylmethyl)-[1,1′-biphenyl]-2-carboxamide
• 英文别名: N-(1,3-benzodioxol-5-ylmethyl)biphenyl-2-carboxamide；N-(1,3-benzodioxol-5-ylmethyl)-2-phenylbenzamide
• CAS: 332129-81-4
• 化学式: C₂₁H₁₇NO₃
• 分子量: 331.371
• InChiKey: UXKUZATVDWGZSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(quinolin-8-yl)-[1,1'-biphenyl]-2-carboxamide 在 4-二甲氨基吡啶 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 24.0h， 生成 N-(benzo[d][1,3]dioxol-5-ylmethyl)-[1,1′-biphenyl]-2-carboxamide
  参考文献：
  名称：

  通过中间N-酰基-Boc-氨基甲酸酯进行8-氨基喹啉酰胺酰胺整体转氨的两步程序

  摘要：

  在本文中，已经探索了实现8-氨基喹啉酰胺的整体转氨基的两步策略。在该方案中，首先将8-氨基喹啉酰胺用Boc 2 O和DMAP处理，以形成相应的N-酰基-Boc-氨基甲酸酯，发现它们具有足够的反应活性，可以在没有任何其他添加剂的情况下用不同的胺进行后续的氨解。试剂或催化剂。为了证明这种方法的实用性，将其应用于最新的C–H官能化文献中的多种8-氨基喹啉酰胺中，从而能够以高产率或高产率获得一系列精细的酰胺衍生物。

  DOI：

  10.1021/acs.joc.8b00174

文献信息

• MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：EP2126574B1

  公开（公告）日：2015-12-23
• Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
  申请人：MOCHLY-ROSEN DARIA

  公开号：US20110105602A2

  公开（公告）日：2011-05-05

  The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.
• MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS FOR PROTECTING, EXPANDING AND INCREASING THE POTENCY OF HEMATOPOIETIC STEM CELLS
  申请人：The Borad of Trustees of the Leland Stanford Junior University

  公开号：US20190083457A1

  公开（公告）日：2019-03-21

  The present disclosure provides methods of protecting and expanding hematopoietic cells. The present disclosure also provides methods of increasing the potency of hematopoietic cells. Aspects of the methods include contacting a starting population of hematopoietic cells with a therapeutically effective amount of at least one ALDH2 agonist. Aspects include in vivo, in vitro and ex vivo methods of protecting, expanding and increasing the potency of hematopoietic cells. Aspects of the methods include treating an individual who is undergoing chemotherapy or radiation treatment for cancer, has been exposed to damaging toxins, has a genetic disease that leads to HSC damage, bone marrow failure, an autoimmune disease, or development of hematologic malignancies. Aspects of the methods also include treating a healthy individual who is a stem cell transplant donor.
• US9102651B2
  申请人：——

  公开号：US9102651B2

  公开（公告）日：2015-08-11
• US9315484B2
  申请人：——

  公开号：US9315484B2

  公开（公告）日：2016-04-19